A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia.

Triglyceride, HDL-C and Atherogenic index of plasma There was a highly significant reduction in TG from 261.11 ± 74.13 mg/dl (baseline) to 171.94 ± 86.51 mg/dl (visit 5) in the amla extract group ( p < 0.0001 within the group), whereas the TG reduction in the placebo group was from 247.62 ± 57.70 mg/dl to 210.47 ± 65.27 mg/dl (Fig. 3 a).

also in 132,142 other papers